SHANGHAI, June 27, 2019 /PRNewswire/ -- Johnson & Johnson Innovation, Division of Johnson & Johnson (China) Investment Ltd., today announced the opening of JLABS @ Shanghai, the world's largest JLABS and the first in Asia Pacific. The 4,400-square-meter facility, located in Shanghai's Zhangjiang Hi-Tech Park, is a collaboration with the Shanghai Pharma Engine Company, Ltd. JLABS @ Shanghai can accommodate more than 50 start-ups across the pharmaceuticals, medical device, consumer and health tech segments, and opens with 31 resident companies, including the three awardees of the Lung Cancer Innovation QuickFire Challenge.
"Johnson & Johnson has deep roots in China with an innovation footprint dating back nearly four decades. We are committed to fueling innovation in the region and unleashing the power of science and technology to advance the health of people in China and around the world," said Paul Stoffels, M.D., Vice Chairman, Executive Committee and Chief Scientific Officer, Johnson & Johnson. "The new JLABS in Shanghai will connect global and local entrepreneurs with the expertise of the Johnson & Johnson Family of Companies and our strategic partners to help transform great ideas into breakthrough solutions."
At the opening, JLABS @ Shanghai announced the awardees of the Lung Cancer Innovation QuickFire Challenge, which was launched in June 2018 to focus on the prevention, interception and curing of lung cancer. The awardees will receive a total of US$750,000 in grants; one year of residency at JLABS @ Shanghai, including a laboratory bench, workstation and access to the JLABS community; and mentorship and coaching from Johnson & Johnson Innovation. The three awardees are: DNX Biopharmaceuticals, Inc., Hawkeye Bio and NE Scientific LLC.
"The opening of JLABS @ Shanghai couldn't have come at a better time for China and the world, facing the growing challenge of diabetes, cancer, and an aging population. Together we can identify and nurture best in class science to transform how diseases are treated, cured, prevented and intercepted," said Melinda Richter, Global Head, Johnson & Johnson Innovation - JLABS[i]. "We can't do that well for the 1.4 billion people in China without being right here, working hand-in-hand with the right people. Today, all of you, and the companies and entrepreneurs of JLABS @ Shanghai, have the potential to create solutions that can be global answers as we work toward the hope of a world without disease."
"Johnson & Johnson is honored to collaborate with the Shanghai Pharma Engine Company Limited to bring JLABS to Shanghai," said Will Song, Chairman, Johnson & Johnson China and President, Johnson & Johnson Medical China[ii]. "JLABS @ Shanghai adds to our expanding presence of R&D, and innovation centers in Shanghai to develop a regional hub for innovation across the Johnson & Johnson Family of Companies and serves as a key contributor to the government's Healthy China 2030 initiative."
JLABS sites have hosted more than 540 companies to date, advancing several biotech, pharmaceuticals, medical device, consumer and health tech programs. JLABS @ Shanghai will follow the same no-strings-attached approach across all existing JLABS locations: San Diego; San Francisco; Boston; Lowell; Houston; Toronto; Beerse, Belgium; New York City and the newly announced Washington, DC. The following companies are the first to be selected as residents of JLABS @ Shanghai:
| JLABS @ Shanghai Resident |
About the Company[iii] |
| Achelois Pharmaceuticals |
Acheloís focuses on the development of T cell medicine |
| Analytics For Life Inc. |
Analytics For Life utilizes non-invasive AI machine- |
| Aprinoia Therapeutics |
Aprinoia Therapeutics focuses on developing novel |
| AsiaBiome |
AsiaBiome is a platform technology for the discovery |
| Beijing Syngentech |
SyngenTech pioneers Synthetic-Biology based live |
| BioSense Suzhou Ltd. |
BioSense focuses on discovering novel kinase inhibitors |
| Black Ceramic Medical Technology |
Black Ceramic Medical Technology focuses on the |
| Bridge Biotherapeutics Inc. |
Bridge Biotherapeutics develops therapeutics for the |
| ChemSun (Cayman) |
ChemSun discovers and develops new innovative next- |
| Corestone Biosciences |
Corestone Biosciences focuses on innovative medical |
| DNX Biopharmaceuticals, Inc. |
DNX Biopharmaceuticals is developing highly innovative |
| Hawkeye Bio |
Hawkeye Bio provides a non-invasive breath test for the |
| Helios Bioelectronics |
Helios Bioelectronics is a semiconductor-based |
| Hepagene Therapeutics (Shanghai), Inc |
Hepagene Therapeutics discovers, develops and delivers |
| HighTide Therapeutics |
HighTide Therapeutics focuses on the development of |
| Holmusk |
Holmusk is a data science and digital therapeutics |
| Inertia Biotechnology |
Inertia Biotechnology develops a direct-to-consumer skin |
| Jiangsu Nuo-Beta Pharmaceutical Technology |
Jiangsu Nuo-Beta Pharmaceutical Technology focuses |
| Lifespans Limited |
Lifespans develops proprietary approaches to making |
| LIVE2LIFE |
LIVE2LIFE develops a cloud |
| Maiden Therapeutics |
Maiden Therapeutics is developing a drug discovery |
| Metabonose |
Metabonose focuses on integrating personalized nutrition |
| mSENSE |
mSENSE develops and provides intelligent and |
| NE Scientific |
NE Scientific develops novel surgical guidance software |
| Octimet |
Octimet develops a family of selective MET kinase |
| Santai Biotech |
Santai Biotech develops develops tissue engineering |
| Shanghai Tuoxiao Intelligent Technology Co. |
Shanghai Tuoxiao Intelligent Technology Co. focuses |
| SpineGuide Technologies |
SpineGuide Technologies is developing an implant for |
| Vigor Medical Systems |
Vigor Medical Systems is a device and digital health |
| Xinguang |
Xinguang focuses on the treatment of metabolic disorders |
Applications to join JLABS @ Shanghai and other JLABS sites are currently being accepted from biotech, pharmaceutical, medical device, consumer and digital health companies. For more information, visit jlabs.jnjinnovation.com.
| About Johnson & Johnson Innovation |
| Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses.
|
| About Johnson & Johnson Innovation – JLABS |
| Johnson & Johnson Innovation – JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators across a broad healthcare spectrum including pharmaceutical, |
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to a new collaboration. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson Innovation LLC and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaboration may not be realized or may take longer to realize than expected; challenges inherent in new product development, including the uncertainty of clinical success and obtaining regulatory approvals; competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2018, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson Innovation LLC and Johnson & Johnson do not undertake to update any forward-looking statement as a result of new information or future events or developments.
| [i] Johnson & Johnson Innovation LLC |
| [ii] Johnson & Johnson Medical (Shanghai) Ltd. |
| [iii] Descriptions were provided by respective companies |
Photo - https://photos.prnasia.com/prnh/20190627/2510496-1-a
Photo - https://photos.prnasia.com/prnh/20190627/2510496-1-b